EAC 2018 Update in Allergy, Asthma and Immunology

Palm Beach, FL US
May 31, 2018 to June 3, 2018

This activity focuses on a national approach in response to the concerns and educational needs of allergists/immunologists.  Both national and regional thought leaders will provide an outstanding educational opportunity to all attendees.  The methodology of reaching out and focusing on healthcare improvement will provide a forum for physicians to discuss and narrow practice gaps in their own practice as well as be updated on recent developments in the diagnosis and treatment of disease states within the fields of allergy and immunology. 

The format is didactic and interactive.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Eastern Allergy Conference. The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support

This activity is supported in part by independent medical education grants from Shire, Greer, CSL Behring, Kaleo and Aimmune.

Target Audience

Practicing allergists, fellow-in-training, primary care physicians and allied healthcare providers in the field of allergy.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Prescribe optimal therapy in patients with food allergy
  • Diagnose and manage drug allergy
  • Diagnose and manage hereditary angioedema
  • Discuss current and future allergy immunotherapy treatment options for peanut and dust mite allergies
  • Describe the pathophysiology, diagnosis and management of allergic skin diseases including chronic urticaria and atopic dermatitis
  • Diagnose and manage chronic cough and cough variant asthma
  • Evaluate for potential immunodeficiency
  • Diagnose and manage COPD
  • Describe the pathophysiology and treatment of severe asthma
  • Describe epigenetics and how it relates to clinical allergy
Additional information
Disclosure: 

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

 

All identified conflicts of interest have been resolved.

 

Leonard Bacharier, MD – Speaker

Speaker - AstraZeneca, Boehringer Ingelheim, Novartis,

Consultant - Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Regeneron, Teva, Vectura, Circassia

Independent Contractor - Sanofi, Vectura  

DSMB Member – DBV Technologies

 

Aleena Banerji, MD – Speaker

Advisory Board - Shire, CSL Behring, BioCryst, Pharming

Independent Contractor - Shire, BioCryst

 

Michael Blaiss, MD – Speaker

Consultant – Alk, Boston Scientific, JDP Therapeutics, Pfizer, Regeneron, Sanofi, Stallergenes, PMD Healthcare

 

Don Bukstein, MD – Speaker

Speaker – Mylan, Optinose, Alk, AstraZeneca, Circassia, Novartis, Genentech,

Consultant – Stallergenes

Independent Contractor – AASC Communications, Alk, Novartis, Genentech

 

William Corrao, MD – Speaker

Speaker – Boehringer Ingelheim

Advisory Board - GlaxoSmithKline

 

Ray Davis, MD – Speaker

Consultant – Alk, Teva, Mylan/Meda, Genentech, Sunovion, Shire, Novartis, Circassia, Pharming

Speaker – AstraZeneca, Teva, Mylan/Meda, Circassia

Advisory Board - DBV Technologies

Independent Contractor – Stallergenes/Greer

 

Matthew Greenhawt, MD – Speaker

Speaker – Hybrid Health, Symbiotix, Thermo Fischer Scientific, Before Brands,

Consultant -  Aimmune, Intrommune, Thermo Fischer Scientific

Advisory Board – Aimmune, Hybrid Health, Kaleo, Nutricia, Symbiotix

 

Lisa Kobrynski, MD – Speaker

Speaker – Association of Public Health Laboratories

Consultant - Association of Public Health Laboratories, Centers for Disease Control

Independent Contractor - Baxter

Grant Reviews – National Institutes of Health

 

Tanya Laidlaw, MD – Speaker 

Consultant – Sanofi

Advisory Board – GlaxoSmithKline, Regeneron

 

 

 

 

Donald Leung, MD – Speaker

Consultant – Regeneron, AbbVie, Sanofi, Pfizer

 

Henry Li, MD  – Speaker

Consultant – CSL Behring, Shire, Pharming

Speaker – CSL Behring, Shire, Pharming

Advisory Board – CSL Behring, Shire, Pharming

Independent Contractor – CSL Behring, BioCryst, Shire, Pharming

Author – CSL Behring, BioCryst, Pharming, Shire

 

Aidan Long, MD – Speaker

Consultant – Novartis, AstraZeneca

Advisory Board - Genentech

 

Hal Nelson, MD – Speaker

Consultant -Alk

Speaker - Alk

 

Peck Ong, MD – Speaker

Consultant – Pfizer, Theravance

 

Lawrence Schwartz, MD – Speaker

Inventor of Tryptase Assay – Thermo Fischer Scientific

Inventor of Tryptase Inhibitor - Genentech

 

Robert Settipane, MD – Planner/Moderator

Independent Contractor -  AstraZeneca, Chiesi, Merck, Teva, Novartis

 

Russell Settipane, MD – Planner/Moderator/Speaker/Reviewer

Speaker – Alk, AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Mylan, Pharming, Regeneron, Sanofi, Shire, Sunovion, Teva

Advisory Board - Alk, AstraZeneca, DBV Technologies, Genentech, Regeneron, Sanofi, Teva

Independent Contractor – AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Novartis, Teva

 

Wayne Shreffler, MD – Speaker

Speaker – Aimmune, DBV Technologies

Consultant – DBV Technologies, Sanofi

Advisory Board – Aimmune

Independent Contractor - Sanofi

 

 

The following have no relevant financial relationships to disclose:

 

Joseph Bellanti, MD – Planner/ Speaker

William Greisner, III, MD – Planner/Moderator/Reviewer

Mark Holbreich, MD - Speaker

Ginny Loiselle – Staff

Elizabeth Matsui, MD – Speaker

Michael Slaughter, MD – Planner/Moderator

Kelli Wilson – Planner/Board Member

Course summary
Available credit: 
  • 15.00 AMA PRA Category 1 Credit™
  • 15.00 Attendance
Course opens: 
05/31/2018
Course expires: 
06/03/2020
Event starts: 
05/31/2018 - 4:30pm CDT
Event ends: 
06/03/2018 - 10:30am CDT
Rating: 
5
The Breakers
One South County Road
Palm Beach, FL 33480
United States
+1 (877) 724-3188

Available Credit

  • 15.00 AMA PRA Category 1 Credit™
  • 15.00 Attendance
Please login or create an account to take this course.